FY2029 EPS Estimates for Compass Therapeutics Cut by Wedbush

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Analysts at Wedbush reduced their FY2029 earnings estimates for shares of Compass Therapeutics in a research note issued to investors on Wednesday, November 5th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of $1.40 for the year, down from their previous estimate of $1.55. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share.

Several other brokerages also recently commented on CMPX. Lifesci Capital started coverage on Compass Therapeutics in a research note on Monday, October 6th. They issued an “outperform” rating and a $10.00 target price for the company. Compass Point set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, October 6th. Guggenheim boosted their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, August 12th. D. Boral Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $12.90.

Compass Therapeutics Trading Up 0.1%

Shares of NASDAQ CMPX traded up $0.01 during mid-day trading on Friday, hitting $4.01. The company had a trading volume of 687,629 shares, compared to its average volume of 1,447,845. Compass Therapeutics has a 1 year low of $1.27 and a 1 year high of $4.86. The company has a market capitalization of $553.81 million, a price-to-earnings ratio of -8.90 and a beta of 1.48. The stock’s 50-day moving average price is $3.76 and its 200-day moving average price is $2.96.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors have recently made changes to their positions in CMPX. Creative Planning purchased a new stake in shares of Compass Therapeutics during the 2nd quarter valued at $30,000. Strs Ohio bought a new position in Compass Therapeutics in the first quarter valued at $34,000. Apollon Wealth Management LLC purchased a new stake in Compass Therapeutics during the third quarter valued at about $35,000. Birchview Capital LP bought a new stake in Compass Therapeutics during the first quarter worth about $46,000. Finally, Walleye Trading LLC purchased a new position in shares of Compass Therapeutics in the 1st quarter worth about $48,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.